对于全球罕见病药物开发商来说，中国及其 14 亿人口可以提供相对庞大的罕见病患者群体。从中国的试验中获得的临床数据也可用于帮助加快美国或欧洲的临床研究。
May
16
© 2024 NGGT Inc. All Rights Reserved. Terms of Use | Privacy Policy | Accessibility Statement
Website developed by Insight Designs
Website developed by Insight Designs
Comments are closed.